This article is more than 5 years old. Information may no longer be current.

CMS issues permanent J-code for Yutiq

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The CMS has assigned a specific and permanent reimbursement J-code for Yutiq, EyePoint Pharmaceuticals announced in a press release.

Yutiq (fluocinolone acetonide intravitreal implant 0.18 mg), a 3-year micro-insert for chronic, noninfectious uveitis, will have the code J7314, effective Oct. 1.

“The October 1st effective date of a permanent J-code specific to Yutiq will allow treating physicians, insurers and patients to benefit sooner from a more streamlined approval and reimbursement process,” Nancy Lurker, president and CEO of EyePoint, said in the release. “This key market access milestone is another positive step forward in our ongoing U.S. commercial launch of Yutiq for this potentially blinding ocular disease.”